Skip to content

Study · Randomized controlled trial · n = 10 · 1986

15 results

Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP).

Köhler M, Hellstern P, Miyashita C, von Blohn G, Wenzel E

Thrombosis and haemostasis1 Feb 1986Cited by 31 (Europe PMC)

PMID3085261 (opens in a new tab)DOI10.1055/s-0038-1661458 (opens in a new tab)PepBankPUB-03085261
Publisher pagePubMedAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

  1. 01HumanRandomized controlled trialActivity measurement

    In healthy volunteers, fibrinolytic activity increased more after intravenous desmopressin than after the other routes.

    In plain wordsIn healthy volunteers, intravenous desmopressin increased fibrinolytic activity more than the other routes.

    Peptide
    Desmopressin
    Outcome
    IncreaseFibrinolytic activity
    Study

    n = 10

    Comparator
    Subcutaneous and intranasal desmopressin
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    The mean increase of fibrinolytic activity was more pronounced after i.v. DDAVP.
    1 context sentence
    Summary · context
    Ten healthy volunteers received DDAVP intranasally (i.n.), subcutaneously (s.c.) and intravenously (i.v.) in a randomized cross-over trial.
  2. 02HumanRandomized controlled trialActivity measurement

    In healthy volunteers, desmopressin had a moderate antidiuretic effect with no apparent differences between administration routes.

    In plain wordsIn healthy volunteers, desmopressin had similar moderate antidiuretic effects across administration routes.

    Peptide
    Desmopressin
    Outcome
    No significant changeAntidiuretic effect
    Study

    n = 10

    Comparator
    Intravenous, subcutaneous and intranasal routes
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The antidiuretic effect was moderate with no apparent differences between the routes of application.
    1 context sentence
    Summary · context
    Ten healthy volunteers received DDAVP intranasally (i.n.), subcutaneously (s.c.) and intravenously (i.v.) in a randomized cross-over trial.
  3. 03HumanNon-randomized trialActivity measurement

    In healthy volunteers, factor XII increased slightly after desmopressin.

    In plain wordsIn healthy volunteers, factor XII increased slightly after desmopressin.

    Peptide
    Desmopressin
    Outcome
    IncreaseFactor XII
    Study

    n = 10

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Factor XII and high molecular weight (HMW)-kininogen levels increased only slightly after DDAVP administration.
    1 context sentence
    Summary · context
    Ten healthy volunteers received DDAVP intranasally (i.n.), subcutaneously (s.c.) and intravenously (i.v.) in a randomized cross-over trial.
  4. 04HumanNon-randomized trialActivity measurement

    In healthy volunteers, HMW-kininogen increased slightly after desmopressin.

    In plain wordsIn healthy volunteers, HMW-kininogen increased slightly after desmopressin.

    Peptide
    Desmopressin
    Outcome
    IncreaseHMW-kininogen
    Study

    n = 10

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Factor XII and high molecular weight (HMW)-kininogen levels increased only slightly after DDAVP administration.
    1 context sentence
    Summary · context
    Ten healthy volunteers received DDAVP intranasally (i.n.), subcutaneously (s.c.) and intravenously (i.v.) in a randomized cross-over trial.
  5. 05HumanNon-randomized trialActivity measurement

    In healthy volunteers, intravenous desmopressin increased factor VIII:C 3.1-fold over baseline.

    In plain wordsIn healthy volunteers, intravenous desmopressin increased factor VIII:C over baseline.

    Peptide
    Desmopressin
    Outcome
    IncreaseFactor VIII:C
    Study

    n = 10

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    Increase over baseline (mean)
    3.1-fold
    intravenous desmopressin; Factor VIII:C

    Source sentences

    Summary
    The mean increase of factor VIII: C was 3.1 (i.v.), 2.3 (s.c.), and 1.3 (i.n.) - fold over baseline.
    1 context sentence
    Summary · context
    Ten healthy volunteers received DDAVP intranasally (i.n.), subcutaneously (s.c.) and intravenously (i.v.) in a randomized cross-over trial.
  6. 06HumanNon-randomized trialActivity measurement

    In healthy volunteers, subcutaneous desmopressin increased factor VIII:C 2.3-fold over baseline.

    In plain wordsIn healthy volunteers, subcutaneous desmopressin increased factor VIII:C over baseline.

    Peptide
    Desmopressin
    Outcome
    IncreaseFactor VIII:C
    Study

    n = 10

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Increase over baseline (mean)
    2.3-fold
    subcutaneous desmopressin; Factor VIII:C

    Source sentences

    Summary
    The mean increase of factor VIII: C was 3.1 (i.v.), 2.3 (s.c.), and 1.3 (i.n.) - fold over baseline.
    1 context sentence
    Summary · context
    Ten healthy volunteers received DDAVP intranasally (i.n.), subcutaneously (s.c.) and intravenously (i.v.) in a randomized cross-over trial.
  7. 07HumanNon-randomized trialActivity measurement

    In healthy volunteers, intranasal desmopressin increased factor VIII:C 1.3-fold over baseline.

    In plain wordsIn healthy volunteers, intranasal desmopressin increased factor VIII:C over baseline.

    Peptide
    Desmopressin
    Outcome
    IncreaseFactor VIII:C
    Study

    n = 10

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    Increase over baseline (mean)
    1.3-fold
    intranasal desmopressin; Factor VIII:C

    Source sentences

    Summary
    The mean increase of factor VIII: C was 3.1 (i.v.), 2.3 (s.c.), and 1.3 (i.n.) - fold over baseline.
    1 context sentence
    Summary · context
    Ten healthy volunteers received DDAVP intranasally (i.n.), subcutaneously (s.c.) and intravenously (i.v.) in a randomized cross-over trial.
  8. 08HumanNon-randomized trialActivity measurement

    In healthy volunteers, intravenous desmopressin increased ristocetin cofactor 3.1-fold over baseline.

    In plain wordsIn healthy volunteers, intravenous desmopressin increased ristocetin cofactor over baseline.

    Peptide
    Desmopressin
    Outcome
    IncreaseRistocetin cofactor
    Study

    n = 10

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    Increase over baseline (mean)
    3.1-fold
    intravenous desmopressin; Ristocetin cofactor

    Source sentences

    Summary
    Ristocetin cofactor (von Willebrand factor antigen) increased 3.1 (2.5), 2.0 (2.3) and 1.2 (1.2) - fold over baseline mean values after i.v., s.c. and i.n. DDAVP, respectively.
    1 context sentence
    Summary · context
    Ten healthy volunteers received DDAVP intranasally (i.n.), subcutaneously (s.c.) and intravenously (i.v.) in a randomized cross-over trial.
  9. 09HumanNon-randomized trialActivity measurement

    In healthy volunteers, subcutaneous desmopressin increased ristocetin cofactor 2.0-fold over baseline.

    In plain wordsIn healthy volunteers, subcutaneous desmopressin increased ristocetin cofactor over baseline.

    Peptide
    Desmopressin
    Outcome
    IncreaseRistocetin cofactor
    Study

    n = 10

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Increase over baseline (mean)
    2-fold
    subcutaneous desmopressin; Ristocetin cofactor

    Source sentences

    Summary
    Ristocetin cofactor (von Willebrand factor antigen) increased 3.1 (2.5), 2.0 (2.3) and 1.2 (1.2) - fold over baseline mean values after i.v., s.c. and i.n. DDAVP, respectively.
    1 context sentence
    Summary · context
    Ten healthy volunteers received DDAVP intranasally (i.n.), subcutaneously (s.c.) and intravenously (i.v.) in a randomized cross-over trial.
  10. 10HumanNon-randomized trialActivity measurement

    In healthy volunteers, intranasal desmopressin increased ristocetin cofactor 1.2-fold over baseline.

    In plain wordsIn healthy volunteers, intranasal desmopressin increased ristocetin cofactor over baseline.

    Peptide
    Desmopressin
    Outcome
    IncreaseRistocetin cofactor
    Study

    n = 10

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    Increase over baseline (mean)
    1.2-fold
    intranasal desmopressin; Ristocetin cofactor

    Source sentences

    Summary
    Ristocetin cofactor (von Willebrand factor antigen) increased 3.1 (2.5), 2.0 (2.3) and 1.2 (1.2) - fold over baseline mean values after i.v., s.c. and i.n. DDAVP, respectively.
    1 context sentence
    Summary · context
    Ten healthy volunteers received DDAVP intranasally (i.n.), subcutaneously (s.c.) and intravenously (i.v.) in a randomized cross-over trial.
  11. 11HumanNon-randomized trialActivity measurement

    In healthy volunteers, intravenous desmopressin increased von Willebrand factor antigen 2.5-fold over baseline.

    In plain wordsIn healthy volunteers, intravenous desmopressin increased von Willebrand factor antigen over baseline.

    Peptide
    Desmopressin
    Outcome
    Increasevon Willebrand factor antigen
    Study

    n = 10

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    Increase over baseline (mean)
    2.5-fold
    intravenous desmopressin; von Willebrand factor antigen

    Source sentences

    Summary
    Ristocetin cofactor (von Willebrand factor antigen) increased 3.1 (2.5), 2.0 (2.3) and 1.2 (1.2) - fold over baseline mean values after i.v., s.c. and i.n. DDAVP, respectively.
    1 context sentence
    Summary · context
    Ten healthy volunteers received DDAVP intranasally (i.n.), subcutaneously (s.c.) and intravenously (i.v.) in a randomized cross-over trial.
  12. 12HumanNon-randomized trialActivity measurement

    In healthy volunteers, subcutaneous desmopressin increased von Willebrand factor antigen 2.3-fold over baseline.

    In plain wordsIn healthy volunteers, subcutaneous desmopressin increased von Willebrand factor antigen over baseline.

    Peptide
    Desmopressin
    Outcome
    Increasevon Willebrand factor antigen
    Study

    n = 10

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Increase over baseline (mean)
    2.3-fold
    subcutaneous desmopressin; von Willebrand factor antigen

    Source sentences

    Summary
    Ristocetin cofactor (von Willebrand factor antigen) increased 3.1 (2.5), 2.0 (2.3) and 1.2 (1.2) - fold over baseline mean values after i.v., s.c. and i.n. DDAVP, respectively.
    1 context sentence
    Summary · context
    Ten healthy volunteers received DDAVP intranasally (i.n.), subcutaneously (s.c.) and intravenously (i.v.) in a randomized cross-over trial.
  13. 13HumanNon-randomized trialActivity measurement

    In healthy volunteers, intranasal desmopressin increased von Willebrand factor antigen 1.2-fold over baseline.

    In plain wordsIn healthy volunteers, intranasal desmopressin increased von Willebrand factor antigen over baseline.

    Peptide
    Desmopressin
    Outcome
    Increasevon Willebrand factor antigen
    Study

    n = 10

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    Increase over baseline (mean)
    1.2-fold
    intranasal desmopressin; von Willebrand factor antigen

    Source sentences

    Summary
    Ristocetin cofactor (von Willebrand factor antigen) increased 3.1 (2.5), 2.0 (2.3) and 1.2 (1.2) - fold over baseline mean values after i.v., s.c. and i.n. DDAVP, respectively.
    1 context sentence
    Summary · context
    Ten healthy volunteers received DDAVP intranasally (i.n.), subcutaneously (s.c.) and intravenously (i.v.) in a randomized cross-over trial.
  14. 14HumanNon-randomized trialActivity measurement

    In healthy volunteers, factor VIII:C half-disappearance time after desmopressin was five hours.

    In plain wordsIn healthy volunteers, factor VIII:C half-disappearance time after desmopressin was five hours.

    Peptide
    Desmopressin
    Outcome
    Not applicableFactor VIII half-disappearance time
    Study

    n = 10

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated

    Measurements

    Half-disappearance time
    5 hours
    factor VIII:C after desmopressin

    Source sentences

    Summary
    The half-disappearance time of factor VIII and von Willebrand factor (vWF) after DDAVP ranged from five (factor VIII:C) to eight hours (vWF).
    1 context sentence
    Summary · context
    Ten healthy volunteers received DDAVP intranasally (i.n.), subcutaneously (s.c.) and intravenously (i.v.) in a randomized cross-over trial.
  15. 15HumanNon-randomized trialActivity measurement

    In healthy volunteers, vWF half-disappearance time after desmopressin was eight hours.

    In plain wordsIn healthy volunteers, vWF half-disappearance time after desmopressin was eight hours.

    Peptide
    Desmopressin
    Outcome
    Not applicablevWF half-disappearance time
    Study

    n = 10

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated

    Measurements

    Half-disappearance time
    8 hours
    von Willebrand factor after desmopressin

    Source sentences

    Summary
    The half-disappearance time of factor VIII and von Willebrand factor (vWF) after DDAVP ranged from five (factor VIII:C) to eight hours (vWF).
    1 context sentence
    Summary · context
    Ten healthy volunteers received DDAVP intranasally (i.n.), subcutaneously (s.c.) and intravenously (i.v.) in a randomized cross-over trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.